Patents by Inventor Shigeru Kamei
Shigeru Kamei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090048180Abstract: A sustained-release preparation which comprises a physiologically active peptide of general formula wherein X represents an acyl group; R1, R2 and R4 each represents an aromatic cyclic group; R3 represents a D-amino acid residue or a group of the formula wherein R3? is a heterocyclic group; R5 represents a group of the formula —(CH2)n—R5? wherein n is 2 or 3, and R5? is an amino group which may optionally be substituted, an aromatic cyclic group or an O-glycosyl group; R6 represents a group of the formula —(CH2)n—R6? wherein n is 2 or 3, and R6? is an amino group which may optionally be substituted; R7 represents a D-amino acid residue or an azaglycyl residue; and Q represents hydrogen or a lower alkyl group, or a salt thereof and a biodegradable polymer having a terminal carboxyl group. The sustained-release preparation shows a constant release of the peptide over a long time and is substantially free from an initial burst.Type: ApplicationFiled: October 7, 2008Publication date: February 19, 2009Inventors: Shigeru Kamei, Yasutaka Igari, Yasuaki Ogawa
-
Publication number: 20080207524Abstract: Medicinal preparations for treating sex hormone-dependent diseases which comprise a combination of a compound having a luteinizing hormone-releasing hormone agonistic effect or its salt with a compound having a luteinizing hormone-releasing hormone antagonistic effect or its salt for administering the compound having a luteinizing hormone-releasing hormone agonistic effect or its salt followed by the compound having a luteinizing hormone-releasing hormone antagonistic effect or its salt. By using these preparations, the concentration of a sex hormone (for example, testosterone, LH, FSH, estrogen) can be quickly recovered after the medicable period of a compound having a luteinizing hormone-releasing hormone antagonistic effect or its salt or a preparation containing the same (preferably a sustained-release preparation), which makes it possible to definitely determine the drug cessation period in an intermittent treatment.Type: ApplicationFiled: November 16, 2007Publication date: August 28, 2008Inventors: Yasutaka Igari, Shigeru Kamei
-
Patent number: 7294344Abstract: The present invention is to provide a sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or their salt, and a biodegradable polymer, and if necessary, a polyvalent metal, and which is highly stable and active and shows angiotensin II antagonistic activity while maintaining circadian rhythm of blood pressure for a long time.Type: GrantFiled: May 22, 2003Date of Patent: November 13, 2007Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasutaka Igari, Akira Saikawa, Yoshiyuki Inada, Shigeru Kamei
-
Patent number: 7048947Abstract: A sustained-release preparation which comprises a physiologically active peptide of general formula wherein X represents an acyl group; R1, R2 and R4 each represents an aromatic cyclic group; R3 represents a D-amino acid residue or a group of the formula wherein R3? is a heterocyclic group; R5 represents a group of the formula —(CH2)n—R5? wherein n is 2 or 3, and R5? is an amino group which may optionally be substituted, an aromatic cyclic group or an O-glycosyl group; R6 represents a group of the formula —(CH2)n—R6? wherein n is 2 or 3, and R6? is an amino group which may optionally be substituted; R7 represents a D-amino acid residue or an azaglycyl residue; and Q represents hydrogen or a lower alkyl group, or a salt thereof and a biodegradable polymer having a terminal carboxyl group. The sustained-release preparation shows a constant release of the peptide over a long time and is substantially free from an initial burst.Type: GrantFiled: April 23, 2002Date of Patent: May 23, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Shigeru Kamei, Yasutaka Igari, Yasuaki Ogawa
-
Patent number: 6883840Abstract: A vehicle outer handle system includes a handle main body formed from a synthetic resin and having a hollow grip part, and an electrode for detecting a change in capacitance. One end of the handle main body is swingably supported in a door outer panel, and the electrode is housed within the grip part. A grounded electrostatic shield plate is disposed with the grip part outwardly of the electrode, thereby preventing an erroneous determination of a user's intention of opening the door.Type: GrantFiled: March 19, 2002Date of Patent: April 26, 2005Assignees: Kabushiki Kaisha Honda Lock, Honda Giken Kogyo Kabushiki Kaisha, Stanley Electric Co., Ltd.Inventors: Masahiko Sueyoshi, Shigeru Kamei, Kazuo Yuhi, Suguru Asakura, Akira Kamikura, Kentaro Yoshimura, Kiyomitsu Ishikawa, Kazuhiko Sugimura
-
Publication number: 20030198676Abstract: The present invention is to provide a sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or their salt, and a biodegradable polymer, and if necessary, a polyvalent metal, and which is highly stable and active and shows angiotensin II antagonistic activity with maintaining circadian rhythm of blood pressure for a long time.Type: ApplicationFiled: May 22, 2003Publication date: October 23, 2003Inventors: Yasutaka Igari, Akira Saikawa, Yoshiyuki Inada, Shigeru Kamei
-
Publication number: 20030176360Abstract: Medicinal preparations for treating sex hormone-dependent diseases which comprise a combination of a compound having a luteinizing hormone-releasing hormone agonistic effect or its salt with a compound having a luteinizing hormone-releasing hormone antagonistic effect or its salt for administering the compound having a luteinizing hormone-releasing hormone agonistic effect or its salt followed by the compound having a luteinizing hormone-releasing hormone antagonistic effect or its salt. By using these preparations, the concentration of a sex hormone (for example, testosterone, LH, FSH, estrogen) can be quickly recovered after the medicable period of a compound having a luteinizing hormone-releasing hormone antagonistic effect or its salt or a preparation containing the same (preferably a sustained-release preparation), which makes it possible to definitely determine the drug cessation period in an intermittent treatment.Type: ApplicationFiled: January 2, 2003Publication date: September 18, 2003Inventors: Yasutaka Igari, Shigeru Kamei
-
Patent number: 6589547Abstract: The present invention is to provide a sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or their salt, and a biodegradable polymer, and if necessary, a polyvalent metal, and which is highly stable and active and shows angiotensin II antagonistic activity while maintaining circadian rhythm of blood pressure for a long time.Type: GrantFiled: August 9, 2000Date of Patent: July 8, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Yasutaka Igari, Akira Saikawa, Yoshiyuki Inada, Shigeru Kamei
-
Publication number: 20030068374Abstract: A sustained-release preparation containing a physiologically active compound slightly soluble in water, a component obtained by treating with water a polyvalent metal compound slightly soluble in water, and a biodegradable polymer which are improved in the release-control and stabilization of the physiologically active compound slightly soluble in water and can be produced by a process suitable for mass production.Type: ApplicationFiled: August 19, 2002Publication date: April 10, 2003Inventors: Shigeru Kamei, Mami Ojima, Takahito Kitayoshi, Yasutaka Igari
-
Patent number: 6528093Abstract: A sustained-release preparation which comprises a physiologically active peptide of general formula: wherein X represents an acyl group; R1, R2 and R4 each represents an aromatic cyclic group; R3 represents a D-amino acid residue or a group of the formula: wherein R3′ is a heterocyclic group; R5 represents a group of the formula —(CH2)n—R5′ wherein n is 2 or 3, and R5′ is an amino group which may optionally be substituted, an aromatic cyclic group or an O-glycosyl group; R6 represents a group of the formula —(CH2)n—R6′ wherein n is 2 or 3, and R6′ is an amino group which may optionally be substituted; R7 represents a D-amino acid residue or an azaglycyl residue; and Q represents hydrogen or a lower alkyl group, or a salt thereof and a biodegradable polymer having a terminal carboxyl group.Type: GrantFiled: August 31, 1999Date of Patent: March 4, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Shigeru Kamei, Yasutaka Igari, Yasuaki Ogawa
-
Publication number: 20030039698Abstract: A sustained-release preparation which comprises a physiologically active peptide of general formula 1Type: ApplicationFiled: August 31, 1999Publication date: February 27, 2003Inventors: SHIGERU KAMEI, YASUTAKA IGARI, YASUAKI OGAWA
-
Publication number: 20020173467Abstract: A sustained-release preparation which comprises a physiologically active peptide of general formula 1Type: ApplicationFiled: April 23, 2002Publication date: November 21, 2002Applicant: Takeda Chemical Industries, Ltd.Inventors: Shigeru Kamei, Yasutaka Igari, Yasuaki Ogawa
-
Publication number: 20020152582Abstract: A vehicle outer handle system includes a handle main body formed from a synthetic resin and having a hollow grip part, and an electrode for detecting a change in capacitance. One end of the handle main body is swingably supported in a door outer panel, and the electrode is housed within the grip part. A grounded electrostatic shield plate is disposed with the grip part outwardly of the electrode, thereby preventing an erroneous determination of a user's intention of opening the door.Type: ApplicationFiled: March 19, 2002Publication date: October 24, 2002Applicant: Kabushiki Kaisha Honda LockInventors: Masahiko Sueyoshi, Shigeru Kamei, Kazuo Yuhi, Suguru Asakura, Akira Kamikura, Kentaro Yoshimura, Kiyomitsu Ishikawa, Kazuhiko Sugimura
-
Publication number: 20020147150Abstract: A sustained-release preparation which comprises a physiologically active peptide of general formula 1Type: ApplicationFiled: December 26, 2001Publication date: October 10, 2002Applicant: Takeda Chemical Industries, Ltd.Inventors: Shigeru Kamei, Yasutaka Igari, Yasuaki Ogawa
-
Patent number: 5972891Abstract: A sustained-release preparation which comprises a physiologically active peptide of general formula ##STR1## wherein X represents an acyl group; R.sub.1, R.sub.2 and R.sub.4 each represents an aromatic cyclic group;R.sub.3 represents a D-amino acid residue or a group of the formula ##STR2## wherein R.sub.3 ' is a heterocyclic group; R.sub.5 represents a group of the formula --(CH.sub.2).sub.n --R.sub.5 ' wherein n is 2 or 3, and R.sub.5 ' is an amino group which may optionally be substituted, an aromatic cyclic group or an O-glycosyl group;R.sub.6 represents a group of the formula --(CH.sub.2).sub.n --R.sub.6 ' wherein n is 2 or 3, and R.sub.6 ' is an amino group which may optionally be substituted;R.sub.7 represents a D-amino acid residue or an azaglycyl residue; andQ represents hydrogen or a lower alkyl group, or a salt thereof and a biodegradable polymer having a terminal carboxyl group.Type: GrantFiled: July 14, 1997Date of Patent: October 26, 1999Assignee: Takeda Chemical Industries, Ltd.Inventors: Shigeru Kamei, Yasutaka Igari, Yasuaki Ogawa
-
Patent number: 5925617Abstract: The present invention is to provide a prophylactic/therapeutic composition for the secondary cataract comprising a polypeptide having an inhibitory activity of cell adhesion and a lactic acid-glycolic acid polymer.The composition of the present invention inhibits adhesion and extension of lens epithelial cells onto the posterior lens capsule after extraction of lens and is useful as a prophylactic/therapeutic composition for the secondary cataract in the clinical point of view.Type: GrantFiled: February 27, 1997Date of Patent: July 20, 1999Assignee: Senju Pharmaceutical Co., Ltd.Inventors: Akira Kiritoshi, Tetsuo Sasabe, Shigeru Kamei, Yasutaka Igari, Noriko Watanabe
-
Patent number: 5716640Abstract: A method of producing sustained-release microcapsules containing a biologically active substance from an W/O emulsion comprising an inner aqueous phase containing said biologically active substance and an external oil phase containing a biodegradable polymer, characterized in that microcapsules formed on microencapsulation of said biologically active substance with said biodegradable polymer are heated at a temperature not lower than the glass transition temperature of said biodegradable polymer but not so high as to cause aggregation of the microcapsules. This method enables the production of very useful sustained release microcapsules adapted to release a bologically active substance at a calculated rate over a protracted time period starting immediately following administration without an initial burst within one day following administration.Type: GrantFiled: August 29, 1996Date of Patent: February 10, 1998Assignee: Takeda Chemical Industries, Ltd.Inventors: Shigeru Kamei, Minoru Yamada, Yasuaki Ogawa
-
Patent number: 5668111Abstract: A sustained-release preparation which comprises a physiologically active peptide of general formula ##STR1## wherein X represents an acyl group; R.sub.1, R.sub.2 and R.sub.4 each represents an aromatic cyclic group; R.sub.3 represents a D-amino acid residue or a group of the formula ##STR2## wherein R.sub.3 ' is a heterocyclic group; R.sub.5 represents a group of the formula --(CH.sub.2).sub.n --R.sub.5 ' wherein n is 2 or 3, and R.sub.5 ' is an amino group which may optionally be substituted, an aromatic cyclic group or an O-glycosyl group;R.sub.6 represents a group of the formula --(CH.sub.2).sub.n --R.sub.6 ' wherein n is 2 or 3, and R.sub.6 ' is an amino group which may optionally be substituted;R.sub.7 represents a D-amino acid residue or an azaglycyl residue; andQ represents hydrogen or a lower alkyl group, or a salt thereof and a biodegradable polymer having a terminal carboxyl group.Type: GrantFiled: June 6, 1995Date of Patent: September 16, 1997Assignee: Takeda Chemical Industries, Ltd.Inventors: Shigeru Kamei, Yasutaka Igari, Yasuaki Ogawa
-
Patent number: 5665394Abstract: The present invention relates to a matrix for sustained-release preparation comprising an ester formed at a terminal carboxyl group of a straight-chain polyester which essentially consists of an .alpha.-hydroxymonocarboxylic acid. The matrix is stable to light, heat, moisture, coloring etc., and is of low toxicity. The sustained-release preparation produced by using the ester of the present invention offers stable drug release over an extended period of time, ensuring sustained stable effect. Furthermore, the sustained-release preparation does not show excess drug release just after administration.Type: GrantFiled: September 30, 1996Date of Patent: September 9, 1997Assignees: Takeda Chemical Industries, Ltd., Wako Purechemical Industries, Ltd.Inventors: Yasutaka Igari, Akira Saikawa, Kayoko Okamoto, Shigeru Kamei, Masahisa Oka, Atsunori Sano
-
Patent number: 5594091Abstract: The present invention relates to a matrix for sustained-release preparation comprising an ester formed at a terminal carboxyl group of a straight-chain polyester which essentially consists of an .alpha.-hydroxymonocarboxylic acid. The matrix is stable to light, heat, moisture, coloring etc., and is of low toxicity. The sustained-release preparation produced by using the ester of the present invention offers stable drug release over an extended period of time, ensuring sustained stable effect. Furthermore, the sustained-release preparation does not show excess drug release just after administration.Type: GrantFiled: February 21, 1995Date of Patent: January 14, 1997Assignee: Takeda Chemical Industries, Ltd.Inventors: Yasutaka Igari, Akira Saikawa, Kayoko Okamoto, Shigeru Kamei, Masahisa Oka, Atsunori Sano